As expected, the model predicts that temozolomide (TMZ) will have a stronger antitumor effect (lower IC50) in glioma patients with MGMT promoter methylation, which reduces expression of the DNA repair enzyme MGMT (Figure 1(BI)). Here, MGMT is linked to central nervous system cancer.